Literature DB >> 20221742

[Visualization of amyloid with positron emission tomography. Useful improvement in the diagnosis of dementia?].

T Grimmer1, A Drzezga, A Kurz.   

Abstract

Imaging techniques for in vivo visualization of cerebral amyloid using positron emission tomography (PET) have been tested in clinical trails over the past 5 years. Based on a selected overview of the literature including our own studies the various radiopharmaceuticals are presented and the current status of research on the validity of amyloid PET imaging as well as its suitability for early and differential diagnosis of Alzheimer's disease (AD) are described. The findings available up to now support the validity of amyloid PET imaging and suggest a possible benefit in differential diagnosis. However, there are as yet no studies with large sample sizes. The possible use for the early diagnosis of AD should be viewed critically, particularly due to the lack of treatment options.

Entities:  

Mesh:

Year:  2010        PMID: 20221742     DOI: 10.1007/s00115-010-2951-6

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  43 in total

1.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.

Authors:  Kooresh Shoghi-Jadid; Gary W Small; Eric D Agdeppa; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Stephen Read; Nagichettiar Satyamurthy; Andrej Petric; Sung-Cheng Huang; Jorge R Barrio
Journal:  Am J Geriatr Psychiatry       Date:  2002 Jan-Feb       Impact factor: 4.105

2.  Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

Authors:  F Hulstaert; K Blennow; A Ivanoiu; H C Schoonderwaldt; M Riemenschneider; P P De Deyn; C Bancher; P Cras; J Wiltfang; P D Mehta; K Iqbal; H Pottel; E Vanmechelen; H Vanderstichele
Journal:  Neurology       Date:  1999-05-12       Impact factor: 9.910

3.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

Authors:  Trey Sunderland; Gary Linker; Nadeem Mirza; Karen T Putnam; David L Friedman; Lida H Kimmel; Judy Bergeson; Guy J Manetti; Matthew Zimmermann; Brian Tang; John J Bartko; Robert M Cohen
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

4.  Magnetic resonance imaging of amyloid plaques in transgenic mice.

Authors:  Youssef Zaim Wadghiri; Einar M Sigurdsson; Thomas Wisniewski; Daniel H Turnbull
Journal:  Methods Mol Biol       Date:  2005

5.  Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

Authors:  Natalie Nelissen; Koen Van Laere; Lennart Thurfjell; Rikard Owenius; Mathieu Vandenbulcke; Michel Koole; Guy Bormans; David J Brooks; Rik Vandenberghe
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

6.  In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.

Authors:  Michelle T Fodero-Tavoletti; David P Smith; Catriona A McLean; Paul A Adlard; Kevin J Barnham; Lisa E Foster; Laura Leone; Keyla Perez; Mikhalina Cortés; Janetta G Culvenor; Qiao-Xin Li; Katrina M Laughton; Christopher C Rowe; Colin L Masters; Roberto Cappai; Victor L Villemagne
Journal:  J Neurosci       Date:  2007-09-26       Impact factor: 6.167

7.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.

Authors:  Kerryn E Pike; Greg Savage; Victor L Villemagne; Steven Ng; Simon A Moss; Paul Maruff; Chester A Mathis; William E Klunk; Colin L Masters; Christopher C Rowe
Journal:  Brain       Date:  2007-10-10       Impact factor: 13.501

8.  Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.

Authors:  A Drzezga; T Grimmer; G Henriksen; M Mühlau; R Perneczky; I Miederer; C Praus; C Sorg; A Wohlschläger; M Riemenschneider; H J Wester; H Foerstl; M Schwaiger; A Kurz
Journal:  Neurology       Date:  2009-04-01       Impact factor: 9.910

9.  Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls.

Authors:  N M Scheinin; S Aalto; J Koikkalainen; J Lötjönen; M Karrasch; N Kemppainen; M Viitanen; K Någren; S Helin; M Scheinin; J O Rinne
Journal:  Neurology       Date:  2009-09-02       Impact factor: 9.910

10.  Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.

Authors:  Yi Li; Juha O Rinne; Lisa Mosconi; Elizabeth Pirraglia; Henry Rusinek; Susan DeSanti; Nina Kemppainen; Kjell Någren; Byeong-Chae Kim; Wai Tsui; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-20       Impact factor: 9.236

View more
  1 in total

1.  Perfusion abnormalities in mild cognitive impairment and mild dementia in Alzheimer's disease measured by pulsed arterial spin labeling MRI.

Authors:  Panagiotis Alexopoulos; Christian Sorg; Annette Förschler; Timo Grimmer; Maria Skokou; Afra Wohlschläger; Robert Perneczky; Claus Zimmer; Alexander Kurz; Christine Preibisch
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-07-24       Impact factor: 5.270

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.